Abstracts

#1082 ENDOMETRIAL MIXED EPITHELIAL CARCINOMA: EPIGENOMICS, TREATMENT AND SURVIVAL — A 10-YEAR RETROSPECTIVE COHORT STUDY FROM A SINGLE INSTITUTION
1Christina Pappa*, 1Valentina Le Thanh, 1Sarah Louise Smyth, 1Andreas Zouridis, 2Joshua Retcher, 1Negin Sadeghi, 1Ammara Khashif, 1Kianoush Zarrindokht, 1Alisha Sattar, 1Stephen Damato, 2Mostafa Abdalla, 1Sean Kehoe, 3Susan Addley, 4Hooman Soleiman Majd. 1Oxford University Hospitals, NHS Foundation Trust, Oxford, UK; 2Royal Berkshire NHS Foundation Trust, Reading, UK; 3Buckinghamshire NHS Foundation Trust, Bucks, UK; 4Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 2University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK

Introduction/Background Mixed endometrial carcinoma refers to rare endometrial tumours that are comprised of two or more distinct histotypes, at least one of which is serous or clear cell. Limited data is available on the recurrence rates for mixed epithelial endometrial carcinoma, as it comprises a relatively understudied subtype of endometrial cancer. The aim of this study is to evaluate the epidemiology, treatment outcomes and survival rates of patients with mixed endometrial carcinoma.

Methodology Medical records of the patients diagnosed with mixed endometrial carcinoma between March 2010 and January 2020 reviewed retrospectively. Clinicopathological variables and treatment strategies were assessed, and overall survival (OS) and disease-free survival (DFS) rates were evaluated.

Results A total of 34 patients were included in the study. Histology of endometrioid and serous component was found in 26 (76.5%) patients, followed by serous and clear cell components (5/34 14.5%) and a mixture of endometrioid, serous and clear cell components (3/34, 8.8%). The median age was 70 years (range 52–84), and median follow-up time was 55 months. Most patients (70%) were treated with laparoscopy. Overall, the 5-year disease-free survival rate (DFS) and the 5-year overall survival rate (OS) were 54.4% and 52.4%, respectively. Advanced disease stage was found to be independently correlated with worse 5-year disease-free survival (DFS) and overall survival (OS) rates (p<0.001).

Conclusion The management of mixed epithelial endometrial carcinoma presents several challenges for clinicians and researchers that need to be addressed to improve oncologic outcomes. Accurate and early diagnosis plays a fundamental role to determine the appropriate treatment plan. Improved diagnostic techniques, such as molecular profiling and imaging technologies, as well as identification of specific biomarkers associated with the distinct features of the tumour, can help clinicians effectively stratify the patients and tailor treatment accordingly. Undoubtedly, the implementation of molecular analysis will offer further diagnostic and management insights.

Disclosures No

#1090 THE MUTATIONAL LANDSCAPE OF UTERINE SARCOMA: IS THERE RATIONALE FOR TARGETED THERAPIES?
Muhammad Daryal Ahsan*, Emily M Webster, Murtaza Oazi, Jessica M Weiss, Sarah Levi, Evelyn Cantillo, Eloise Chapman-Davis, Kevin Holcomb, Ravi N Sharaq, Melissa K Frey. Weill Cornell Medicine, New York, USA

Introduction/Background We aimed to characterize the mutational landscape of uterine sarcoma.

Methodology Data were extracted from the American Association for Cancer Research’s (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database version 13.1 via cBioPortal (http://genie.cbioportal.org). We queried this database for uterine sarcoma samples and analyzed frequencies of pathogenic gene variants (PGVs) for which targeted therapies are currently available or in clinical trials for other cancer types. These included PGVs associated with homologous recombination deficiency (HRD): ATM, ARID1A, ATRX, BRCA1, BRCA2, BARD1, BRIPI, BLM, BAP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, MRE11, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, WRN; PGVs associated with the MAP-kinase signaling pathway: BRAF (V600E), KRAS, NRAS, EIF1AX; PGVs associated with mismatch repair (MMR): MSH2, MSH3, MSH6, MLH1, MLH3, PMS2, EPCAM; PGVs in other genes: PTEN, PIK3CA, MTOR, CDKN2A, CDKN2B, and ERBB2 (amplification).

Results A total of 704 uterine sarcoma tumor samples from 680 patients were included for analysis. At least one somatic PGV was observed in an HRD associated gene in 27.8% (196/704) of all tumors, with the most common PGVs observed in ATRX (109/645, 16.9%), BRCA2 (27/652, 4.1%) and RAD51B (16/435, 3.7%). At least one somatic PGV was observed in an MMR associated gene in 3.0% (21/704) of all tumors, with the most common PGVs observed in MSH6 (6/648, 0.9%) and MSH2 (5/633, 0.8%). At least one somatic PGV was observed in a MAP-kinase associated gene in 2.8% (20/704) of all tumors, with the most common PGVs observed in KRAS (14/680, 2.1%). Highest frequencies of other targetable PGVs were observed in PTEN (89/677, 13.1%) and PIK3CA (16/680, 2.4%).

Conclusion The high rate of PGVs in HRD genes and PTEN in uterine sarcoma tumor samples suggests the need for clinical trials evaluating the efficacy of genetically targeted therapies for this patient population.

Disclosures No relevant conflict of interest disclosures for any of the co-authors.

#1099 ONCOLOGICAL QUALITY OF OPEN, LAPAROSCOPIC, AND ROBOTIC SURGERY IN EARLY-STAGE ENDOMETRIAL CANCER, A NATIONWIDE, POPULATION-BASED CANCER REGISTRY STUDY IN TAIWAN
1Arthur Heng-Cheng Hsu*, 2Chun-Ju Chiang, 3San-Lin You, 4Hui-Shan Liu, 5Dennis Chin-Lun Huang. 1Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan; 2Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; 3School of Medicine and Data Science Center, Fu Jen Catholic University, New Taipei City, Taiwan; 4Department of Obstetrics and Gynecology, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan; 5Clinical Affairs, Intuitive Surgical Sarl Taiwan Branch (Switzerland), Taipei, Taiwan

Introduction/Background Surgical treatment is the cornerstone for women with early-stage endometrial cancer, which has been seen an increasing incidence in Taiwan. Minimally invasive surgery (MIS) is associated with less complications, little is known for the comparison of open and MIS approaches in Taiwan. Preliminary results are reported here.

Methodology We used the Taiwan Cancer Registry (TWCR), which is a nationwide and population-based database, to collect data. Between 2018 and 2020, women with early-stage endometrial cancer who underwent staging surgery and had...